Femasys

Yahoo Finance • 14 days ago

Femasys Announces Third Quarter Financial Results for 2025

– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Femasys... Full story

Yahoo Finance • 26 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change MSP Recovery Inc. 437,923,706 0.8807 0.52 0.7959 +0.5759 EZGO Technologi... Full story

Yahoo Finance • 26 days ago

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

--Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- --$12 million senior secured convertible notes for total potential proceed... Full story

Yahoo Finance • last month

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, is please... Full story

Yahoo Finance • 3 months ago

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

ATLANTA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced the introd... Full story

Yahoo Finance • 3 months ago

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

ATLANTA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced it has rec... Full story

Yahoo Finance • 3 months ago

Femasys (FEMY) Falls 27% as Firm to Raise $8-Million from Share Sale

We recently published 10 Stocks Losing Big. Femasys Inc. (NASDAQ:FEMY) is one of the worst performers of Tuesday. Femasys extended losses to a second day on Tuesday, slashing 27 percent to close at $0.3760 apiece as investor sentiment was... Full story

Yahoo Finance • 3 months ago

Femasys Prices $8 Mln Public Offering To Fund Product Development And Commercial Expansion

(RTTNews) - Femasys Inc. (FEMY) has priced an underwritten public offering totaling approximately $8 million through the sale of 10.43 million shares of common stock or pre-funded warrants, along with common warrants to purchase up to 22.1... Full story

Yahoo Finance • 3 months ago

Top stock movements in today's session.

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 90.28% INVIVYD INC'S... Full story

Yahoo Finance • 3 months ago

Tuesday's session: top gainers and losers

Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis. [topmovers] TOP GAINERS TICKER CHANGE COMMENT NUKKW [https://www.ch... Full story

Yahoo Finance • 3 months ago

Traders are paying attention to the gapping stocks in Tuesday's session.

In today's session, there are notable price gaps in the US markets on Tuesday. Take a closer look at the stocks that are gap up and gap down. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT HKPD [https://www.chartmill.com/s... Full story

Yahoo Finance • 3 months ago

Tuesday's pre-market session: top gainers and losers

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 132.0% Investors witness... Full story

Yahoo Finance • 3 months ago

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

ATLANTA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, acc... Full story

Yahoo Finance • 4 months ago

Femasys GAAP EPS of -$0.16

* Femasys press release [https://seekingalpha.com/pr/20195248-femasys-announces-second-quarter-financial-results-for-2025] (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]): Q2 GAAP EPS of -$0.16. * Sales increased by $187,784, or 8... Full story

Yahoo Finance • 4 months ago

Femasys Announces Second Quarter Financial Results for 2025

-- Continued Progress on Regulatory Approvals and Global Commercialization of Fertility Portfolio -- ATLANTA, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgica... Full story

Yahoo Finance • 4 months ago

Femasys secures first European order for FemBloc

* Femasys (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]) on Wednesday announced its entry into Europe with an order of about $400,000 for FemBloc Permanent Birth Control in Spain. * FemBloc is a non-surgical solution for permanen... Full story

Yahoo Finance • 6 months ago

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

-- Femasys continues to expand access and market share for its first-line infertility treatment option, FemaSeed® -- ATLANTA, June 11, 2025 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing sig... Full story

Yahoo Finance • 6 months ago

Femasys announces pricing of underwritten public offering and concurrent private placement with gross proceeds of $4.5M

* Femasys (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]) on Friday announced the pricing of an underwritten public offering of 3.6M shares of its common stock at a public offering price of $0.85 per share and a separate concurrent... Full story

Yahoo Finance • 6 months ago

Femasys announces public offering, concurrent private placement

* Femasys (NASDAQ:FEMY [https://seekingalpha.com/symbol/FEMY]) plans to sell common stock in an underwritten public offering. A 30-day option will be granted to underwriters to purchase up to 15% additional shares. * All securities in... Full story

Yahoo Finance • 6 months ago

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, acce... Full story